Analysis of the significance of the new disease name"metabolic dysfunction-associate steatotic liver disease"CHEN Si-tong, XU Hang-fei, WEI Xiao-die, ZHAO Jin-han, ZHANG Yang, ZHANG Jing1-6
Clinical research progress of nonalcoholic fatty liver disease and liver transplantationMAI Zi-ling, CHANG Bing, LI Yi-ling7-10,16
Clinical research progress of hepatitis B virus infection concurrent with metabolic dysfunction-associated fatty liver diseaseMA Xiao-yan, GENG Nan, RUI Fa-juan, NI Wen-jing, SHI Jun-ping, LI Jie17-21,32
Epidemiological status and prevention and treatment progress of nonalcoholic fatty liver disease in childrenZHANG Xin-he, GUAN Lin22-28
Nonalcoholic fatty liver disease-related hepatocellular carcinoma:what we know and unknownDENG Chao-hua, SHI Jun-ping29-32
Expert consensus on off-label drug use of Liaoning province in hematological diseases(2023 edition)The Lymphatic System Foundation and Clinical Immunity Branch of Liaoning Immune Society,Shenyang 110001,China, YANG Wei33-41
Clinical analysis of BTK inhibitors combined with basic chemotherapy in newly diagnosed double expression diffused large B cell lymphomaYANG Dan, LI Feng, YANG Fei-fei, ZHAO You-cai, XU Yan-li, ZHANG Xue-zhong, ZHANG Xiu-qun42-48
Hypoxia-inducible factor prolyl hydroxylase inhibitor on the effect of infection events in patients with peritoneal dialysisDING Jia-xiang, REN Xiao-ying, FANG Xiao-wan, WANG Mei, YANG Qing-hua49-53,85
Remnant cholesterol is associated with the risk of mildly reduced estimated glomerular filtration rateWANG Peng-bo, YE Ning, GUO Xiao-fan, WU Jing, SUN Ying-xian54-58